Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
Status:
Not yet recruiting
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
This study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of
Cadonilimab in combination with gemcitabine/cisplatin as a first-line treatment for recurrent
or metastatic nasopharyngeal carcinoma.